Abstract 28P
Background
Obesity and related diseases, namely, diabetes and metabolic syndrome, are associated with chronic inflammation and colorectal cancer (CRC). In CRC liver metastases (mCRC) and adjacent liver tissue defects are formed in the mitochondrial electron transport chain that causes mitochondrial dysfunction, activation of redox-molecules (SR, NO) generation sources and MMP-2, -9 activity. Radical oxygen species take a part in the regulation of gelatinases (MMP-2 and -9) and the xanthine/xanthine oxidase reaction is widely used as a source of exogenous ROS in considering of MMPs. The aim of the study was to determine the state of XO, SR and MMPs in liver tissue and CRC liver metastases (MT) and set the clinical significance of obtained results.
Methods
The prospective study on 37 mCRC patients who underwent the liver resection due metastatic disease has been performed. The rate of SR generation of neutrophils and in the tissue samples, the rate of XO and the activity of matrix metalloproteinases in the tissue samples was measured accordingly study design.
Results
The highest level of XO in mCRC patients was detected in metastatic tissue (1.47±0.18 a.u.). The level of XO enzyme in the adjacent tissue (AT) and distant tissue (DT) were 0.38±0.10 a.u. (p<0.05) and 0.19±0.008 a.u. (р<0,05) respectively. A correlation was found between the BMI and amount of XO in DT of the liver r2 = 0,64. The total activity of gelatinases in subgroup of mCRC patients with BMI ≥ 25 was found to be significantly higher than in normal body weight patients withing the DT (1.52; p<0.001), as well as in the AT (1.28 times; p<0.001). High XO levels (HR (95% CI) = 0,002 (2,63 to 15.05) P = 0,002) and SR generation levels (HR (95% CI) = 0,01 (2,4 to 10,37) P = 0,01) in adjusted liver tissue to metastatic lesions had a negative impact on overall overall survival rates.
Conclusions
Xanthine oxidase and superoxide radicals can be a new metastatic disease prognostic factors for colorectal cancer patients, the latter requiring further randomized trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients
Presenter: Anastasia Frolova
Session: Poster session 09
25P - Role of AXL activation on adaptive resistance to KRAS-G12C inhibitors in KRAS-G12C-mutated non-small cell lung cancer
Presenter: Tadaaki Yamada
Session: Poster session 09
26P - Pre-clinical modelling and treatment of BRAF mutated colorectal cancer
Presenter: Mark White
Session: Poster session 09
27P - Extending a classification system for atypical BRAF mutations to improve targeted therapies in colorectal cancer cells
Presenter: Abhinav Madduri
Session: Poster session 09
29P - The effect of cancer associated fibroblast-derived activin A on colorectal cancer progression
Presenter: Simone Stang
Session: Poster session 09
30P - Prostaglandin signaling in tumour stroma interaction in colorectal cancer and its impact on the secretome and functional relevance
Presenter: Mario Macia-Guardado
Session: Poster session 09
31P - Cell-free tumor microRNA as early biomarkers of high-grade cervical intraepithelial neoplasia using liquid biopsy
Presenter: Stéphanie Calfa
Session: Poster session 09
32P - Epigenetic reprogramming induced prostaglandin E2 accumulation via overactivated arachidonic acid metabolism during trastuzumab resistance formation of HER2-positive breast cancer
Presenter: yongmei yin
Session: Poster session 09
33P - Visualizing trastuzumab-deruxtecan action in HER2+ breast cancer cells at nanoscale
Presenter: Katia Cortese
Session: Poster session 09
35P - SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models
Presenter: Sukanya Patra
Session: Poster session 09